GH is believed to be widely employed in sports as a performance-enhancing substance. Its use in athletic competition is banned by the World Anti-Doping Agency, and athletes are required to submit to testing for GH exposure. Detection of GH doping is challenging for several reasons including identity/similarity of exogenous to endogenous GH, short half-life, complex and fluctuating secretory dynamics of GH, and a very low urinary excretion rate. The detection test currently in use (GH isoform test) exploits the difference between recombinant GH (pure 22K-GH) and the heterogeneous nature of endogenous GH (several isoforms). Its main limitation is the short window of opportunity for detection (ϳ12-24 h after the last GH dose). A second test to be implemented soon (the biomarker test) is based on stimulation of IGF-I and collagen III synthesis by GH. It has a longer window of opportunity (1-2 wk) but is less specific and presents a variety of technical challenges. GH doping in a larger sense also includes doping with GH secretagogues and IGF-I and its analogs. The scientific evidence for the ergogenicity of GH is weak, a fact that is not widely appreciated in athletic circles or by the general public. Also insufficiently appreciated is the risk of serious health consequences associated with high-dose, prolonged GH use. This review discusses the GH biology relevant to GH doping; the virtues and limitations of detection tests in blood, urine, and saliva; secretagogue efficacy; IGF-I doping; and information about the effectiveness of GH as a performance-enhancing agent. (Endocrine Reviews 33: 155-186, 2012)
I. Introduction
T he use of GH as a performance-enhancing agent is believed to be widespread among both professional athletes and adolescents participating in sports (1) (2) (3) (4) . GH is classified as a prohibited substance on the World Anti-DopingAgency(WADA)ProhibitedList[http://www.wada-ama. org/en/World-Anti-Doping-Program/Sports-and-AntiDoping-Organizations/International-Standards/ProhibitedList/]. Aspects of GH that are attractive to athletes are its purported ergogenic activity, aid in recovery from injury, and "undetectablity" (Table 1) . A detailed time line of the use of GH in sports is presented in Holt et al. (5) . This review critically evaluates the scientific underpinnings of GH use in sports, with particular emphasis on strategies and methods of detection of exogenous GH administration.
II. Background Information on GH Structure, Function, and Regulation
GH is a pituitary polypeptide hormone with anabolic and growth-promoting activity. Both its structure and function are species-specific. The only GH with bioactivity in humans is human GH (hGH) or the closely related primate GH (6, 7) . In contrast, hGH is biologically active in a number of lower species, a feature that has been termed "one-way species specificity." hGH also has lactogenic activity, a feature that is lacking in nonprimate GH. This review will only discuss hGH because animal GH are not pertinent in the context of doping in humans.
A. GH genes
The human genome contains five GH-related genes, located in the GH gene cluster on chromosome 17q24.2. This locus occupies approximately 47 kilobases and contains two GH genes-GH-N (or GH1) and GH-V (or GH2)-as well as the related chorionic somatomammotropin (CS) (also known as placental lactogen) genes (8) . These multiple genes are believed to have arisen by gene duplication. Each of the five genes in the cluster is composed of five exons and four introns. The GH-N gene is expressed in pituitary somatotrope cells and, to a minor extent, in lymphocytes, whereas GH-V and CS genes are expressed in the placenta. The level of GH gene expression in lymphocytes may be sufficient to play a local paracrine/ autocrine immunoregulatory role, but it is insufficient to fulfill a hormonal role at distant sites. In the absence of pituitary (or placental) GH gene expression, there is no detectable GH in blood, and the clinical features of severe GH deficiency ensue.
B. Primary GH gene products
The main product of the GH-N gene is a 191-amino acid, 22,129 molecular weight (mol wt), single chain, simple (unmodified) protein with two disulfide bridges (Fig.  1) . It is the prototype pituitary GH and is known as 22K-GH. It is also the recombinant GH available for therapeutic use (and for doping purposes). Another GH isoform, the 20K-GH variant, is also derived from the GH-N gene by alternative mRNA splicing (9) ; it has a structure analogous to 22K-GH, except for the deletion of internal residues 32-46. It has 176 amino acids and a mol wt of 20, 274 . It arises from the use of an alternative splice site in exon 3 and is expressed at 5-10% of the expression level of 22K-GH. A third isoform (17.5K-GH), arising from skipping of exon 3 and lacking residues 32-71, has been proposed as an additional GH variant based on the finding of a transcript (10) . This form has not been shown to be expressed in significant amounts under normal physiological conditions.
The GH-V gene product, GH-V, GH2 or placental GH, is a 191-amino acid, 22,321 mol wt, single chain protein with two disulfide bridges, similar in structure to 22K-GH ( Fig. 1) . Its sequence differs from that of 22K-GH at 13 amino acid positions. It contains a consensus sequence for N-glycosylation at position 140 and exists as both a glycosylated and a nonglycosylated form. The GH-V gene does not produce significant amounts of a 20K variant (11, 12) . GH-V is exclusively produced by the placenta and during pregnancy progressively supplants GH-N in the maternal circulation (13, 14) . It has similar somatogenic activity as GH-N but has reduced lactogenic activity (15) (16) (17) .
CS is also produced by the placenta in considerable amounts. It has about 85% structural homology with GH, but has no significant somatogenic bioactivity. GH-V and CS will not be further discussed in this review because they have limited relevance for GH doping. Thus, the term "GH" will refer to hGH-N and its isoforms.
C. GH isoforms
GH is not a single protein, but consists of several molecular variants (isoforms). A detailed treatise on GH isoforms has recently been published (18) ; a synopsis tailored to the purposes of the current review follows ( Table 2) . The principal and most abundant GH form in pituitary and blood is monomeric 22K-GH. This is also the isoform produced commercially for therapeutic purposes, known as "recombinant GH." Because of its availability, it is also the form typically used for GH doping. The 20,000 mol wt variant, known as 20K-GH, is the second most abundant isoform in pituitary and plasma (5-10% of total GH) (19, 20) . It has a propensity to dimerize, and its dimer is enriched compared to the 22K-GH-dimer (19, 21, 22) . Recombinant 20K-GH has been produced pharmaceutically (23) but was never developed for therapeutic use. Whether TABLE 1. Rationales given for using GH as a doping agent in sports it is available for illicit use is currently unknown. Several posttranslationally modified monomeric GH forms exist; they include two deamidated forms (Asn  137 and Asn   152 ), N ␣ -acylated, and glycosylated [an O-linked N-acetylhexosamine-hexose-(neuraminic acid) 2 glycomoiety at Thr 60 has been proposed] 22K-GH (24 -27) . Proteolytically cleaved GH forms are not considered native forms (20) . GH isoforms also exist as an oligomeric series of at least up to pentameric GH, with both covalent (disulfide-linked) and noncovalently associated oligomers. Homo-as well as heterooligomers composed of the described monomeric forms have been described. Oligomers are present in the pituitary, are secreted as such, and circulate in blood (21, 22, 28, 29) .
D. GH structure
The tertiary structure of monomeric 22K-GH (and 20K-GH) is a four-helix, antiparallel, twisted bundle characteristic of the cytokine family of proteins (30) . Crystal structures have not been obtained for the other GH isoforms, but it is likely that they retain the same overall conformation. Part of helix 1 and the loop between helices 1 and 2 with its embedded minihelix are missing in 20K-GH (30) .
E. The GH receptor (GHR)
GH action is initiated by its binding to the GHR in target tissues. The GHR is a plasma membrane-resident receptor of the cytokine receptor class I superfamily (31) . It is expressed ubiquitously and is particularly abundant in the liver (32, 33) . The GHR primary structure differs among species, and the species specificity of GH action is dictated by high-affinity interaction of GH with its cognate GHR. GH has two receptor binding epitopes on its surface; upon binding of a GHR to site 1, a second GHR The black dot at the amino terminus denotes the acyl (probably acetyl) group in N-acylated GH. The two asterisks denote the deamidated residues in desamido-GH forms. The amino acid designations next to the main chain denote the residues that are changed in placental GH (GH-V). The tree structure at residue 140 indicates the glycosylation site in glycosylated GH-V. [Reproduced from G. Baumann: Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 12:424 -449, 1991 (20) , with permission. © The Endocrine Society.] binds to site 2, forming a 2:1 complex between GHR and GH (34) . The two GHR exist in a predimerized form; binding of GH leads to a conformational change of the dimer followed by signal transduction (35) (36) (37) . The GHR signals through several intracellular phosphorylation cascades, of which the JAK2-Stat5b pathway is particularly important for its growth-promoting activity (37, 38) . The other pathways include the IRS-PI3K, SHC-MAPK, PIPAkt, Stat 1 and 3, and other signaling cascades; their discussion goes beyond the scope of this review.
hGH also interacts with the prolactin receptor (39) ; it is unclear whether it can fully supplant the role of prolactin in lactation. Animal GH do not bind to the prolactin receptor, although in some species (e.g., cow) GH promotes milk production through the GHR. This property is the basis for the commercial use of bovine GH in the dairy industry. Table 3 lists the principal biological activities of GH. Of particular interest to the athlete are its anabolic and lipolytic activities. From these properties alone it has been assumed that GH must be an ergogenic, performance-enhancing substance.
F. Biological activities of GH
The various GH isoforms have qualitatively similar bioactivities in humans (reviewed in Ref. 18 ). The reduced diabetogenic activity attributed to 20K-GH based on some rodent data has not been confirmed in human subjects (40). Among the monomeric forms, their in vivo bioactivity appears to be similar in both qualitative and quantitative terms. Oligomeric GH forms generally have reduced bioactivity compared with GH monomers as assessed by in vitro assays; there is only limited information about their bioactivity in vivo (18) .
G. Regulation of GH secretion
GH is secreted from the pituitary gland in a pulsatile fashion under dual hypothalamic control by GHRH (stimulatory) and somatostatin (inhibitory). Ghrelin, derived from the stomach and possibly the hypothalamus, plays at best a minor role in physiological GH secretion. [In contrast, ghrelin and its synthetic congeners (GH secretagogues, GHS) or GH-releasing peptides (GHRP) are potent pharmacological stimuli for GH secretion when administered in vivo.] GH secretory pulses occur every 2-3 h and vary greatly in amplitude (41-43) (Figs. 2 and  3 ). The largest pulses generally occur at night and are associated with stage IV (slow wave) sleep, typically in the early phases of the sleep cycle. The ultradian pattern of GH secretion differs between the sexes, with women having generally higher secretion rates/serum levels, more erratic secretion patterns, and higher interpeak (basal) GH secretion/serum levels compared to men (Fig. 2) . This difference is attributable to an estrogen effect (44).
The GH secretion rate peaks during adolescence and declines thereafter throughout life, with an approximately 15% decline per decade (45). Obesity attenuates GH secretion; undernutrition and physical fitness enhance it (45-47). Acute physiological stimuli for GH release are sleep, exercise, stress, and fasting (46, 48 -50). The GH response to exercise has been well-documented and reviewed in detail (51-55). GH inhibits its own secretion through both short loop (autofeedback) (56, 57) and long loop (IGF-I-mediated) feedback (58, 59) (Fig. 4) . Feedback regulation occurs both at the hypothalamic (principal site of GH autofeedback) and pituitary levels (main but not exclusive site of IGF-I feedback). Additional feedback regulation of GH secretion occurs through metabolic factors elicited by GH action (e.g., free fatty acids, glucose).
With respect to GH isoform secretion, there is no evidence for differential regulation of isoforms. Rather, it appears that all isoforms are cosecreted during a secretory burst (60 -63) (Fig. 3) .
H. Metabolism and clearance
A major portion of the metabolic clearance of monomeric GH occurs in the kidney, with efficient glomerular filtration followed by extensive degradation in the proximal tubule (64 -68). Only approximately 1/10,000th of glomerularly filtered GH is excreted in the final urine (69, 70) . Other sites of metabolic clearance are the liver and other tissues, where GH is cleared via GHR-mediated cellular uptake and intracellular degradation. There is little quantitative information available on this process and how it is distributed among organs; the liver is thought to be an important site because the GHR is abundantly expressed in that organ.
The plasma half-life of total (free and GH-binding protein bound) GH is approximately 14 -18 min (see Section II.I for discussion of GH-binding proteins) (67, 71). Estimates for free and bound GH are 11 and 27 min, respectively (72) . The half-life of 20K-GH is somewhat longer (19 -25 min) than that of 22K-GH (61, 62). It is not clear whether this property is due to its tendency for dimer formation, thereby slowing renal clearance, to its lower affinity for the GHR, or both. Similarly, the clearance of oligomeric GH forms is also slower than that of monomeric GH; with reported plasma halflives of 19, 27, and 45 min for monomeric, dimeric, and oligomeric GH, respectively (73) . The slower clearance of 20K-GH and oligomeric forms is reflected in the (compared with 22K-GH) longer half-life of "pituitary GH," which contains all these isoforms (61). Because of the differences in clearance rates, the relative proportions of GH isoforms in blood change over time, with relative accumulation of the more slowly cleared forms (61). This is the main reason for the observation that 20K-GH and oligomeric GH forms tend to be proportionately higher in blood than in the pituitary (74) . The pharmacokinetics of exogenous 22K-GH in healthy young volunteers after iv injection show a plasma half-life of 22 min, a volume of distribution of 70 ml/kg, and a clearance rate of 135 ml/kg ⅐ h (75). After sc injection, a plasma peak is achieved at 4 h, the half-life is 3.8 -4 h, the clearance rate is 179 ml/kg ⅐ h, and plasma GH stays elevated for at least 12 h (62, 75) (Fig. 5) . After im injection, the values are similar to those after sc administration, except that the peak is reached earlier (at 2 h) and the half-life is 4.9 h (75). It should be noted that half-lives after sc or im administration are not true half-lives, but represent a combination of continued absorption and elimination kinetics. Absolute bioavailability is listed as 75% after sc and 63% after im injection (75) . The pharmacokinetics of exogenous 20K-GH in healthy young subjects, as assessed in a single study using sc administration, showed a plasma peak time of 3.7 h and a half-life of 1.9 -2.9 h (76).
Administration of either 22K-GH or 20K-GH suppresses endogenous GH secretion for at least 12 h, as evidenced by the absence of secretory pulses of 20K-or 22K-GH, respectively (62, 76) (Fig. 5 ).
I. GH in blood
After secretion, GH rapidly associates with two circulating GH binding proteins (GHBP) (Fig. 4) . Binding to the main (high-affinity) GHBP is readily reversible and follows a dynamic equilibrium. The high-affinity GHBP is the ectodomain of the GHR, generated from the GHR by the action of the metalloproteinase TNF-␣ converting enzyme (see Ref. 77 for review). The low-affinity GHBP has been shown to correspond to the transformed form of ␣ 2 -macroglobulin (78) . Under basal conditions (GH level Ͻ10 ng/ml), 45-55% of 22K-GH and ϳ25% of 20K-GH is bound to the highaffinity GHBP, and 5-7% is bound to the lowaffinity GHBP. At higher GH levels (Ͼ20 ng/ ml), the fraction of GH bound to the highaffinity GHBP declines due to saturation of the GHBP (79) . The circulating complexes have mol wt of ϳ85,000 and Ͼ 150,000, respectively. GHBP protect GH from renal clearance and degradation; the complexes serve as a circulating GH pool, prolonging the bioavailability of GH. In addition, GHBP competes with GHR for GH binding and may inhibit signaling, thereby modulating GH bioactivity. The high-affinity GHBP can interfere with GH measurement in serum (see Section II.L).
Serum GH levels are conventionally reported as total (bound ϩ free) GH. They fluctuate widely, reflecting the pulsatile secretion from the pituitary (Figs. 2 and 3 ). In the basal state (interpulse levels), GH levels range between 0.01 and 1 ng/ml. After a secretory pulse, they may range between 1 and 100 ng/ml. The boundary between a basal level and a small pulse is ill-defined and somewhat arbitrary. Pulse detection algorithms, such as cluster and deconvolution, can help define what constitutes a pulse. The highest serum GH peaks are typically seen at night (during slow-wave sleep) and generally reside in the 10 -20 ng/ml range. Occasionally, peaks can be considerably higher. During the day, GH peaks are typically smaller, in the 2-10 ng/ml range. The spectrum of GH pulse amplitudes extends over at least two orders of magnitude, and peaks of widely varying height can occur at any time. Age, gender, body mass index/adiposity, physical activity, stress, time of day, and nutritional and metabolic status all influence GH secretion.
Most GH immunoassays do not fully discriminate between GH isoforms but may differ partially in their recognition of isoforms; this has implications for GH measurement by immunoassay (see Section II.L). Isoform- specific immunoassays have been developed for 22K-GH and 20K-GH (and placental GH). Using these assays, the proportion of 20K-GH as part of total serum GH ranges between 3 and 28%, with an average of 5-9%, and with no consistent differences between adults, children, genders, ages, or physiological states (61-63, 74, 80, 81) . No specific assays exist for the other GH-N related isoforms; their proportions in serum (Table 2) are derived from physicochemical separation followed by polyvalent immunoassay (82) (83) (84) (85) (86) .
The stability of GH in blood is high. GH is an inherently stable protein with a long shelf life when purified. Degradation within blood is minimized by the high concentration of protease inhibitors present in plasma (87) . GH concentrations in serum or plasma stored at 4 C or at Ϫ20 C are not changing significantly over days to weeks (88) (G. Baumann, personal observation). Incubation of pituitary GH with human blood plasma at 37 C for up to 24 h has not revealed detectable degradation products (89) . No statistically significant changes in serum immunoreactive GH concentrations were found after 24 h at room temperature, 2-7 d at 2Ϫ8 C, or 6 months at Ϫ15 C (90) . Thus, GH is not subject to significant intravascular metabolism or degradation in blood plasma or serum stored ex vivo.
J. GH in urine
Small amounts of GH are excreted in the urine. Despite the fact that glomerular filtration is the main route of GH clearance, the uptake and degradation of filtered GH in the proximal nephron is so efficient as to leave only a minute fraction (ϳ0.01%) to reach the final urine (69, 70) . This process is mediated by the multispecific megalin-cubulin-amnionless receptor system, which leads to endocytosis of filtered proteins followed by their proteolytic digestion in lysosomes (see Ref. 91 for review). Thus, urinary GH excretion accounts for less than 0.005% of the GH secreted by the pituitary or administered exogenously (69, 70, 92, 93) . Nevertheless, even these small amounts are readily measurable by modern immunoassays (94 -100) . In older, less sensitive assays requiring larger sample volumes, the high osmolality of urine caused interference and spuriously high readings (70, 92, 101) .
With respect to urinary excretion of GH isoforms, there is only very limited information. Baumann and Abramson (70) showed evidence of the presence of monomeric 20K-GH and acidic GH forms in urine but found no evidence for dimeric or oligomeric GH. Similarly, Mauri et al. (102) reported only monomeric GH in urine. This would be expected based on molecular size restriction at the glomerular sieve. There are only two reports that show evidence for 20K-GH in the urine (70, 103) .
The stability of GH in stored urine was evaluated by Main et al. (95) , who showed stability at Ϫ20 C for 2 wk but a 25% loss over 7 months, whereas GH remained stable when stored at Ϫ80 C for the same period.
The amount of GH excreted in the urine is highly variable, both between subjects and within the same individual from day to day, with intraindividual coefficients of variation of 40 -60% (95, 104, 105) . Numerous studies in the 1990s evaluated the potential utility of 24-h urinary GH excretion as a diagnostic tool for disorders of GH secretion, such as hypopituitarism, GH deficiency, and acromegaly (94 -98, 100, 104 -109 ; only a few selected references are listed here, but a complete list is available from the author upon request). Urinary GH excretion rises after administration of exogenous GH (106, 110) , but there is limited information and likely overlap with normal excretion rates. In all, over 3200 subjects have been evaluated, representing a robust database on urinary GH excretion. The results of these studies can be summarized as follows. 1) The amount of GH excreted in normal sub- jects in a 24-h period ranges between 0.3 and 80 ng, a greater than 100-fold range, with the majority of values between 2 and 15 ng per 24 h. 2) Excreted amounts vary widely among subjects for reasons that are poorly understood. 3) On a population basis, urinary GH excretion roughly follows trends of plasma GH (e.g., values are lowest in hypopituitarism, high during puberty, highest in acromegaly, etc.), but there is substantial overlap between these categories. 4) Among individuals, there is no correlation between 24-h integrated plasma GH levels and urinary GH excretion. 5) No correlation is found between urinary GH excretion and auxological measurements in children. 6) Day-to-day variation in excretion renders the interpretation of a single measurement unreliable. 7) The intra-and intersubject variability far exceeds that which can be attributed to analytical imprecision and disparities among assays. And 8) Individual urine GH measurements are too variable to be useful as a tool for clinical diagnosis, even in conditions at the extremes of the GH secretion spectrum (i.e., hypopituitarism and acromegaly). GH excretion is also strongly impacted by renal factors, such as proteinuria of pathological or physiological origin (including exercise-induced proteinuria) (107, 108, 111) . Renal insufficiency also leads to increased GH excretion (112) . For all these reasons, the scientific literature on urinary GH excretion has largely fallen silent in the last decade. Two recent publications reported the use of isopropylacrylamide hydrogel particles loaded with Cibacron Blue to concentrate GH from urine before immunoassay (113, 114) . The GH concentrations measured by that technique are lower (Ͻ1 pg/ml) than those by direct assay. Unfortunately, no recovery data were reported, and it appears likely that adsorptive losses may have contributed to incomplete recovery of GH from the particles. This would be expected at such low protein concentrations and would explain the lower values. No results were reported on isoforms extracted from urine. It is not clear whether concentration of GH from urine is advantageous over direct measurement using high-sensitivity assays.
K. GH in saliva
There is little information on the presence of GH in saliva. One study in normal subjects reported salivary GH levels to be 1000-fold lower than those in serum and a significant correlation between salivary and serum GH concentrations (115) .
L. GH measurement
GH in biological fluids can be measured by in vitro bioassay, radioreceptor assay, or immunoassay. Bioassays and radioreceptor assays are not suitable for routine purposes, are highly vulnerable to interference from GHBP, and are generally used only in the research setting. Immunoassays are of either the single-site competitive type or the two-site sandwich type [radioimmunoassay (RIA), immunoradiometric assay (IRMA), enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA)], and use radioactivity, colorimetry, fluorescence, or chemiluminescence as a readout. Modern immunoassays in clinical use are of the two-site immunometric design and are highly sensitive. Most antibodies recognize all GH isoforms, but a few isoform-specific assays exist for 22K-GH, 20K-GH, and placental GH. Disparities of results obtained by different assays of up to at least 100% have been reported, depending on reagents, epitope recognition among GH isoforms, assay design (equilibrium vs. nonequilibrium, incubation time, and temperature), and matrix effects. Important, but not exclusive, reasons for assay disparities are differential recognition of GH isoforms and interference by the high-affinity GHBP. Typically, modern monoclonal, nonequilibrium assays are more affected than older, polyclonal assays with longer incubation times. This topic has been reviewed in detail (116, 117) . Efforts are under way to harmonize GH measurements in clinical chemistry laboratories as much as possible, and a recent workshop of the GH Research Society, the IGF Society, and the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) has addressed this issue (118) . Although assay discrepancies present a significant problem in the clinical arena, they are less of a concern in the antidoping field because absolute levels of GH are not a major endpoint in detection of GH abuse.
Nonimmunological, mass-based measurements of GH in biological fluids [e.g., mass spectrometry (MS)] are currently not used because of insufficient sensitivity of these methods at the GH levels prevailing in blood or urine. Efforts are being made to improve sensitivity with the goal to develop MS-based assays for GH in serum (119, 120) .
III. Strategies for Detection of GH Abuse
The fact that exogenous GH is identical to the main form of endogenous GH (22K-GH) renders its detection challenging. Thus, conventional forensic identification methods for foreign substances are not applicable. Furthermore, the pulsatile secretion pattern of GH makes it difficult, if not impossible, to interpret a high serum GH level as evidence for GH doping. Two main strategies for detection have been developed: the GH isoform test and the biomarker test. Both are currently applicable only to blood samples.
A. The GH isoform test
The GH isoform test is a direct detection method (by itself not definitive, for reasons mentioned above) com-bined with a biological response based on suppression of endogenous GH secretion by exogenous GH. This general strategy, first proposed by Wu et al. (121) and Momomura et al. (103) , was further developed (90) and tested at the Olympic Games in 2004 (Athens), 2006 (Turin), and 2008 (Beijing); it is now in general use as a WADA-sanctioned test. In essence, the test consists of two GH immunoassays: one that is relatively specific for 22K-GH and another that is "permissive," that is it recognizes a number of pituitary isoforms in addition to 22K-GH. It is not known to what degree the various GH isoforms (except for 20K-GH; see Section III.A) are measured by the permissive test, but such knowledge is not critical for antidoping purposes. A dose of exogenous GH suppresses the endogenous forms, including 22K-GH, 20K-GH, and other isoforms (Fig. 5) . Thus, the ratio between 22K-GH and pituitary GH increases because most of the measurable GH is of exogenous origin (90, 121) . For validation purposes, WADA requires two independent assays, and thus two separate pairs of 22K-GH-specific (named "rec" for recombinant) and permissive (named "pit" for pituitary) antibodies are used in two independent assays (named A and B) (90) (Fig.  6 ). Using these assays, the normal rec/pit ratio has a median value of approximately 0.8 and ranges from 0.1 to 1.2. The median value of less than 1 reflects the fact that 22K-GH accounts for only 75-80% of the GH isoforms. The current rec/pit ratio cutoffs ("decision limits") used by WADA for evidence of doping is 1.81 for men and 1.46 for women (assay kit 1) and/or 1.68 for men and 1.55 for women (assay kit 2) (122). These values have been derived from the analysis of athlete samples obtained under realworld doping control conditions and are designed to yield a combined test specificity (between the two kits) of 99.99%. Of interest, none of the four assays in current use measures 20K-GH because the detection antibody used for signal generation does not recognize 20K-GH (90) . Replacement of the detection antibody with one that also recognizes 20K-GH would probably be advantageous because 20K-GH is an important constituent of pituitary GH. It has been suggested that the permissive assay could/ should be replaced by a specific 20K-GH assay, which would be chemically better defined and scientifically more rigorous (103, 123) . Although correct, this idea would be disadvantageous if an athlete were to use a mixture of 22K-GH and 20K-GH in physiological proportions. It is unknown whether recombinant 20K-GH, which has been pharmaceutically produced but not marketed, is available on the black market. With the permissive assay, it is unlikely that an athlete could duplicate a normal pattern unless he or she were taking cadaveric GH or using a GH secretagogue. Thus, both specific assays and permissive assays have their unique advantages and disadvantages. It may be possible in the future to supplement the existing isoform test with one that specifically measures the 22K-GH/20K-GH ratio, keeping the above-mentioned relative ease of evading detection by such a test in mind. All four assays used in the GH isoform test show some cross-reactivity with GH-V (placental GH) (90) , raising the question of applicability of the test in pregnant women. Interference by GH-V is negligible at levels below 10 ng/ml, which in normal pregnancy are not reached until the end of the second trimester (13, 14) . Since most women in their third trimester are not likely to participate in competitive sports, and since pregnancy is usually obvious at that stage, GH-V cross-reactivity in the GH isoform test is not a significant problem in practice.
The isoform test is an excellent strategy to detect GH doping, provided it is administered shortly after the last GH dose (within ϳ24 -36 h, depending on the dose) (90), realistically probably within 12-24 h. A recent placebocontrolled study of the detection time window in young men after administration of recombinant GH (33 g/kg, or ϳ2.3 mg for a 70-kg person), and using the currently employed WADA assays, procedures, and decision thresholds, showed a postinjection duration of test positivity of 14.5 Ϯ 5.5 h (mean Ϯ SD) (248) . In the same study, repeated daily administration of the same dose of GH for 2 wk and sequential testing revealed that blood samples obtained 10 h after the preceding GH dose always tested positive, whereas samples taken 21 h after the preceding dose always tested negative. This short window of opportunity has been the Achilles heel of the isoform test, with the first positive result occurring only after more than 2 yr of general implementation encompassing more than 1500 tests (124) . This experience is not indicative of presumed (and in some cases acknowledged) use of GH; it can be explained by the athletes stopping GH injections at least 1 d before an expected test. The test, therefore, is not well suited for in-competition testing. Its use in unannounced out-of-competition testing, however, should be more successful in catching GH abusers, and recently it has been used mostly in that setting. Despite that, at the time of this writing (November 2011), only eight positive findings have been recorded among over 3400 tests, one of them in an athlete possessing a therapeutic use exemption (248) . One likely reason for this relatively low "yield" is the high decision threshold, designed to protect the athlete by minimizing false-positive results. As experience with the test and data for the normative range accrue, it is possible that the cutoff values for positivity can be set at a more stringent level, allowing better discrimination between users and nonusers without sacrificing the conservative nature of the test.
The strategy used for the blood isoform test would be theoretically applicable to a urine isoform test. Indeed, limited data have shown that urinary GH excretion rises after administration of exogenous GH (103, 106, 110) , presumably representing the injected 22K-GH. Very little information is available about suppression of endogenous GH isoforms in urine; one publication showed no suppression or even slightly higher urinary 20K-GH levels after administration of GH, although the 20K/22K ratio was lower because of the elevated 22K-GH level (103) . Reliable detection of minor isoforms in urine is a substantial challenge, given the low concentrations of total GH in urine. Additional difficulties would be those discussed in Section II.J, including lack of scientific background information about isoform handling by the kidney, distorted isoform profiles because of glomerular filtration cutoffs, nonspecific influences such as proteinuria, and most importantly, the same short window of opportunity that applies to blood testing.
B. The biomarker test

GH biomarkers and the biomarker test in blood
The GH biomarker test is an indirect test based on downstream biochemical changes resulting from GH action. Well-known effects of GH are the induction of IGF-I expression and promotion of collagen turnover in bone and connective tissues (125) . Thus, IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) have been selected as relatively specific GH-responsive biomarkers suitable for an antidoping test. [Other GH-dependent biomarkers considered but not ultimately selected for various reasons (discussed in Section B.1) were IGF-binding protein (IGFBP) 2 and IGFBP3, acid-labile subunit (ALS), and markers of bone turnover, such as procollagen type I amino-terminal propeptide (PINP) and carboxy-terminal propeptide (PICP), osteocalcin, and type I collagen carboxyterminal cross-linked telopeptide (ICTP).] Major efforts have been made by the GH-2000/GH-2004 consortium, the Australian-Japanese consortium, and other groups to validate the biomarker test under various circumstances (age, gender and ethnicity, elite vs. recreational athletes vs. the general population, type of sport, effect of training, injury, anabolic steroid or erythropoietin use, etc.). A substantial database regarding these GH biomarkers and conditions has been accumulated over the past one to two decades. The history of the development of the biomarker test has been summarized by Sö nksen (126) and Holt et al. (5) .
IGF-I, a 70-amino acid peptide with three disulfide bridges and a mol wt of 7649, is an important mediator of many GH actions and exhibits mitogenic, anabolic, and insulin-like metabolic activities. It shares structural and functional features with insulin and acts through the type 1 IGF receptor (also known as IGF-1 receptor), which shares homology with the insulin receptor. IGF-I binds with high affinity to the IGF-1 receptor and with lower affinity to the insulin receptor. At physiological concentrations, most of IGF-I action is mediated through the IGF-1 receptor. GH is the principal regulator of IGF-I production in healthy individuals. IGF-I is synthesized and released into the bloodstream by the liver in response to GH; it is also produced as a paracrine/autocrine factor in many other GH-responsive tissues, with some spillover into the circulation (Fig. 4) . The liver accounts for the majority (ϳ75%) of circulating IGF-I (127). IGF-I in blood is bound to six IGFBP in ternary and binary complexes. Ternary complexes, formed with IGFBP3 and IGFBP5, also contain another GH-dependent protein, ALS, as the third component (Fig. 4) . The majority of circulating IGF-I is bound in the IGFBP3/ALS/IGF-I complex. The protein-bound state of IGF-I in blood is responsible for its long circulating half-life.
P-III-NP, a protein with mol wt of approximately 40,000, is a by-product of type III collagen biosynthesis. Type III collagen is a constituent of numerous tissues, including the vasculature, skin, intestines, and other viscera; its distribution is ubiquitous as a component of blood vessels. Procollagen is secreted in soluble form into the extracellular space, where it undergoes condensation to a triple helix under the guidance of its C-terminal propeptide domain, which serves as a nucleation focus. After this, both the C-terminal and N-terminal propeptides are cleaved from procollagen by bone morphogenetic protein 1 and one or more metalloproteinases of the ADAMTS family, respectively, and released into the lymphatic system and bloodstream (see Ref. 128 for review). P-III-NP is a trimeric protein composed of three identical partial procollagen ␣1(III) polypeptide chains, which in humans contain 129 amino acids and have a mol wt of 13,116 each (129 -132). P-III-NP consists of an amino-terminal globular region, a central triple helical region, and a carboxy-terminal telopeptide region; these domains are named Col 1, Col 3, and Col 2, respectively (133, 134) (Fig. 7) . The trimer is stabilized by two interchain disulfide bridges near the carboxy-terminus and by a collagen-like triple helix formation in the central Col 3 domain (135). P-III-NP is a very acidic protein (pI-ϳ3) due to sulfation in the Col 1 domain; the precise residue(s) carrying sulfate has not been identified (130). A consensus sequence for N-linked glycosylation exists near the carboxy-terminus, but no glycosylated P-III-NP has been described. The globular Col 1 domain appears to be the principal epitope recognized by polyclonal antisera generated against P-III-NP (130). Human and bovine P-III-NP have 95% sequence identity (131), and human, bovine and porcine P-III-NP show complete cross-reactivity in polyclonal immunoassays (130, 136). The principal immunoreactive region resides in the Col 1 domain; this is a conformational epitope because the intact P-III-NP trimer is much more immunoreactive than the monomeric peptide (130, 137, 138). Monoclonal antibodies have been developed, but it has been difficult to define the exact epitopes recognized because of the complexities inherent in P-III-NP and its isoforms and degradation products (for review, see Ref. 139).
P-III-NP circulating in blood is heterogeneous and consists of at least four immunoreactive forms of different molecular size (see Refs. 134 and 140 for review) (Fig. 8) . Intact P-III-NP is a minority component designated Peak III on gel filtration chromatography. Peak II, with molecular size about twice that of P-III-NP, is thought to be a P-III-NP dimer [i.e., a hexamer of monomeric partial procollagen ␣1(III) chains]. Peak I is of high mol wt and remains largely uncharacterized. It may represent P-III-NP aggregates, P-III-NP bound to plasma proteins, or incompletely cleaved P-III-NP still attached to the rest of the collagen molecule (also known as pN-collagen type III). Peak IV has a smaller molecular size than P-III-NP and is assumed to be the Col 1 fragment and/or degradation product(s) of P-III-NP, or a species unrelated to procollagen III. To date, none of these interpretations of the nature of P-III-NP size variants has been corroborated by direct chemical analysis. Of importance, depending on the immunoassay, these different molecular species are recognized to different degrees. The two commercial assays cur- The blood levels of both IGF-I and P-III-NP increase in response to GH and disappear with reported half-lives of 90 and 700 h, respectively (141). These values are probably overestimates of true plasma half-lives, which are 14 -18 h for IGF-I in man (142) and ϳ60 min for P-III-NP in the pig (143) (no human data on plasma P-III-NP halflife are available). The discrepancies may be explained by continued production of the biomarkers for some time after cessation of GH dosing and, in the case of P-III-NP, generation of high mol wt immunoreactive degradation products with long half-lives (143). In any case, serum immunoreactive IGF-I and P-III-NP remain elevated for about 4 d and 2-8 wk, respectively, depending on the GH dose (144 -146) (Fig. 9) . Unlike the pulsatile pattern of GH in blood, their serum levels remain relatively constant throughout the day and between days (147). Thus, although less specific than a direct test for GH, biomarkers have the practical advantage of a longer window of opportunity for detection. The biomarker test is also potentially applicable to the detection of IGF-I abuse, and studies to assess this possibility are in progress (see Section V).
Two concerns exist with respect to the biomarker test: 1) lack of specificity and vulnerability to factors not related to GH or IGF-I; and 2) limitations of available assays. In addition, test interpretations are complicated by ageand sex-dependent variation.
With respect to specificity of IGF-I, few if any conditions elevate IGF-I as consistently as GH. One possibility is obesity, which can result in mildly increased serum IGF-I, but most studies show no correlation between body mass index and serum IGF-I. Furthermore, obesity is not likely to be a major confounder in most sports, with the possible exception of Sumo wrestling. Neither exercise nor injury significantly affects IGF-I levels, although in some subjects exercise resulted in a mild and transient (Ͻ30 min) increase in serum IGF-I that may represent hemoconcentration (148, 149). Sports injuries have been shown to have either no effect or only a minimal effect on IGF-I (150, 151). Even after major injury (tibia fracture), the transient IGF-I response is much lower than that obtained with even a modest GH dose (15 g/kg ⅐ d; ϳ1 mg/d) (151). Testosterone administration does not alter IGF-I levels or the response of IGF-I to GH (152). Similarly, erythropoietin has no effect on IGF-I levels (153). Thus, serum IGF-I is a very good biomarker for GH action; its only drawback is the relatively short duration of elevation (a few days).
The specificity of P-III-NP is not as narrow as that of IGF-I. Its plasma levels have been evaluated in the context of exercise and injury. Exercise increased P-III-NP levels in some studies but not others, and when present, the rise was much smaller than what is seen after GH administration (reviewed in Ref. 149). After an injury, collagen turnover is expected to be increased as part of the healing process, and indeed P-III-NP levels rise after sports injuries. After a soft tissue injury, they peak at 2 wk and are back to baseline after 7 wk; after a bony injury, they peak at 6 wk and return to baseline after 12 wk (150). However, the rise is relatively minor compared to that which occurs after GH administration (150). Similarly, other markers of collagen and bone turnover (small fragment of C-terminal cross-linked telopeptide of type I collagen (CTX) and osteocalcin) after tibial fracture show elevations that are substantially lower than those seen with GH treatment (151). Erythropoietin has no effect on P-III-NP levels (153), but testosterone administration mildly increases P-III-NP and enhances its response to GH (152). However, this effect appears insufficient to adversely affect the dis- criminant function (see below) used to distinguish GH abusers from nonusers (5).
Because both IGF-I and P-III-NP levels change as a function of age, with a peak in adolescence and a gradual, lifelong decline thereafter (paralleling the age-dependent changes in GH secretion), values must be interpreted against an age-appropriate normative range. Similarly, gender and possibly ethnicity affect these biomarkers, which requires interpretation against appropriate normative ranges. IGF-I levels tend to be higher in women, whereas collagen markers, including P-III-NP, are higher in men. Extensive study of these parameters in elite athletes, both immediately after a competitive event and at random times (representing out-of-competition conditions) have shown that age and gender are the major confounders, whereas ethnicity and sport type have only a minor influence (149, 154 -156) .
The dynamics of IGF-I and P-III-NP during and after GH treatment can be summarized as follows (152): IGF-I rises rapidly to near peak levels within 2 wk after starting GH, with P-III-NP following more slowly to near peak levels within 4 -6 wk. After cessation of GH treatment, IGF-I falls most rapidly to reach baseline after 7 d, whereas P-III-NP declines more slowly toward near-baseline after 4 wk and fully to baseline by 6 wk. Thus, IGF-I is more useful as a detection tool in the early phases of both initiation and cessation of GH use, whereas P-III-NP is most useful for the later time points after cessation.
The combined values of IGF-I and P-III-NP have been used to devise a discriminant formula that separates GH users from nonusers and thus can be used as a practical GH doping detection test (146). The discriminant functions are different for men and women, they take age into account, and they are based on biomarker values obtained in specific commercial immunoassays (see Section III.B.4 for comments on the latter). Using these formulae, a positive doping test score has been proposed at a threshold that is predicted to yield a false-positive reading in no more than 1 in 10,000 tests, i.e., at a Z value of at least 3.72 (146, 157) . Because of the above-mentioned dynamics, the test relies increasingly on P-III-NP as time elapses after stopping GH use, and P-III-NP is therefore given more weight. For the biomarker test as currently designed, a window of opportunity of several days following cessation of GH exists. In normal volunteers given doses of approximately 2-4 mg of GH daily, the test remained positive following cessation of GH in 69 -79% after 2 d, in 53-64% after 5 d, and in 20% after 14 d (146). The duration of this window of opportunity is dose-dependent, varies among individuals, and tends to be longer in men. A realistic estimate in practice may be 1 wk, although a window of up to 14 d has been suggested (5) .
Intraindividual fluctuations in biomarkers over time have been examined, and coefficients of variation ranging from 14 to 20% for IGF-I and 7 to 18% for P-III-NP have been found (147, 158) . This degree of variability did not interfere with the performance of the discriminant function (147). Both IGF-I and P-III-NP show the most rapid changes during adolescence under the influence of pubertal up-regulation of GH secretion. A study in adolescent elite athletes has confirmed that the discriminant function remains valid as a determinant of GH abuse even in this most demanding circumstance (159), but particular caution is probably advisable for the interpretation of results in adolescents.
GH biomarkers other than IGF-I and P-III-NP have also been investigated for their suitability for a detection test; they include several members of the IGF system and various markers of collagen and bone turnover. Most have been less extensively studied than IGF-I and P-III-NP, and some were not further pursued because they were judged to be less well-suited for a detection test than those two biomarkers. Among members of the IGF system, IGFBP3, IGFBP2, and ALS were shown to be less responsive to GH treatment than IGF-I (144, 152, 160). Among collagen and bone markers, osteocalcin, procollagen type I aminoterminal propeptide (PINP), carboxy-terminal propeptide (PICP), and type I collagen carboxy-terminal cross-linked telopeptide (ICTP) were found to respond less vigorously to GH and return to baseline more quickly after GH cessation than P-III-NP (141, 145, 160 -162). Other considerations include the inherent variability of a biomarker within or between subjects, or as a function of gender and ethnicity, which from the standpoint of a detection test should be kept to a minimum (158, 163) . The aggregate of all these observations led to the selection of IGF-I and P-III-NP as the currently most suitable biomarker pair for development of a GH doping detection test.
Biomarkers in urine
Biomarker testing is currently only applicable to blood; its potential use as a urine test faces significant obstacles. There is little information on how the kidney handles IGF-I or P-III-NP. Based on insulin excretion data (164), it can be assumed that (free) IGF-I is filtered at the glomerulus and extensively taken up and degraded in the proximal tubule, akin to the fate of GH described in Section II.J. A similar renal degradation process has been shown for P-III-NP (165) . There is evidence that IGF-I is directly produced by the kidney and excreted in the urine (166, 167) . Some studies have examined urinary IGF-I in clinical and antidoping contexts, whereas there is very little information on urinary P-III-NP. Tö nshoff et al. (168) reported urinary IGF-I concentrations of 0.08 Ϯ 0.07 ng/ml, which did not change after 3 d of GH treatment. Gill et al. (98) showed widely varying excretion rates (0 -1350 ng/24 h) in normal adults and a similar range of values (0 -950 ng/24 h) in matched patients with severe organic GH deficiency. Similarly, no difference in IGF-I excretion rates was shown between GH-deficient and GH-sufficient children and adolescents (169) . Attempts to use urinary IGF-I as a diagnostic tool for IGF deficiency or excess states were abandoned when it was realized that urinary IGF-I does not correlate with serum IGF-I and does not reflect underlying GH secretion status (98) . De Palo et al. (170, 171) compared IGF-I excretion in sedentary individuals and trained cyclists before and after strenuous exercise. They found a wide interindividual range of IGF-I excretion (0 -350 ng/liter) and a 240% increase in excretion after exercise. A highly significant correlation existed between urinary total protein and IGF-I, but no correlation was found between plasma IGF-I and urinary IGF-I. A weak correlation was shown between urinary GH and urinary IGF-I excretion, but this was mostly dependent on a few outlier values. The urinary IGF-I/urinary GH molar ratio showed major differences between sedentary subjects, cyclists before exercise, and cyclists after exercise (means of 190, 15, and 577, respectively). The high variability of these findings may be explained by inherent variability of IGF-I (and GH) excretion, exercise-induced proteinuria (including IGF-I and GH), and renal production of IGF-I not reflective of plasma IGF-I. Pichini et al. (172) compared urinary IGF-I values in sedentary individuals and recreational and elite athletes and also found wide ranges and overlaps among the three groups, without consistent changes in response to training and competition. Uemasu et al. (173) examined the effect of exogenous GH administration on urinary IGF-I excretion and found that despite the expected increase in serum GH and IGF-I, urinary IGF-I output actually decreased significantly. Taken together, the available literature on urinary IGF-I can be summarized as follows. 1) Urinary IGF-I excretion is highly variable, ranging from undetectable to 1000 ng/24 h with an approximate mean of 130 -450 ng/24 h, depending on the study. 2) Urinary IGF-I excretion does not reflect serum IGF-I or GH secretion rate in clinical studies.
3) Exercise increases urinary IGF-I, an effect that can be at least partially attributed to exercise-induced proteinuria. And 4) The administration of GH does not raise urinary IGF-I excretion. Thus, the biology of IGF-I in urine does not appear to be an index of GH status and is unlikely to be useful for detection of illicit GH use. Furthermore, because IGFBPs are also present in urine (98, 169, 172, 174) , the use of urine does not avoid the problem of IGFBP interference in IGF-I measurements (see Section III.B.4), thereby not conferring an analytical advantage over the use of blood.
With respect to urinary P-III-NP, one publication listed a daily excretion of P-III-NP immunoreactivity of 30 -110 g, but indicated that this represented the Col 1 fragment rather than the intact peptide (175) . Another recent publication reports a range of 2-110 ng/mmol creatinine (corresponding to an excretion rate of roughly 20 -1430 ng/24 h) in subjects with normal renal function (176) . The vast majority of this activity is kidney-derived, rather than blood-derived, and urinary P-III-NP is increased in patients with renal disease resulting in fibrosis (176) . The scientific background information on urinary P-III-NP and its relation to GH is insufficient to permit contemplation of a detection test for GH abuse based on urine P-III-NP at this time. The nature of the limited data available raises doubts about the feasibility of a robust urine test.
Urinary excretion of other, small collagen biomarkers [N-and C-terminal cross-linked telopeptides of type I collagen (NTX and CTX), pyridinoline, deoxypyridinoline, and hydroxyproline] is known to be highly variable and subject to diurnal fluctuation, which necessitates 24-h urine collections (177) . Because of these characteristics, their measurement has proven to be of limited diagnostic value in the assessment of clinical bone disorders. Although these urinary biomarkers have not been examined in an antidoping context, the experience in the clinic does not support their suitability for a reliable GH detection test.
Biomarkers in saliva
Saliva has also been considered as a biological fluid for IGF-I measurement. Limited data show that salivary IGF-I concentration is 40-to 200-fold lower than serum IGF-I, and that its source is at least in part derived from local synthesis in the salivary gland (178 -181) . Early suggestions of using saliva as a diagnostic tool to assess GH deficiency or excess states have not been adopted because salivary GH did not reliably identify such conditions (180). Antonelli et al. (182, 183) examined salivary IGF-I in athletes and found that they had lower levels than control subjects, and that after exercise IGF-I levels rose in saliva, but not in blood. No reports have yet appeared on the response of salivary IGF-I to exogenous GH. Taken together, the published data suggest that salivary IGF-I may bear a rough relationship to serum IGF-I and GH, but that its biology is poorly understood and its correlation with GH status is insufficient to yield a robust detection tool for GH abuse.
Analytical considerations and challenges
a. IGF-I measurement. Currently the measurement of IGF-I in blood is conducted by immunoassay. Its assay presents significant challenges, primarily because of interference by IGFBPs. The "gold standard" for IGF-I measurement in serum is acidification, which dissociates the complexes, followed by removal of binding proteins by acid gel filtration on a sizing column. This technique is laborious and not amenable to routine, high throughput use. Alternative methods are acid-ethanol precipitation, extraction of IGF-I on C 18 Sep-Pak cartridges, dissociation of complexes with acid followed by blocking of rebinding with excess IGF-II, and conducting the assay in commercial "dissociation buffers." The latter likely contain IGF-II. None of these methods are successful in completely removing IGFBP interference. As a result, major disparities in results exist among assays. This issue has been recently reviewed in detail (118, 184) .
An additional problem with IGF-I measurement lies with the international reference standard, against which assays are calibrated. The World Health Organization international reference reagent 87/518 is not pure and therefore has an artificially high weight assignment. In addition, its stocks are depleted, and a new, pure international reference reagent (02/254) has been adopted. Assays calibrated against the new standard will yield lower results, thereby rendering comparisons with earlier studies difficult. Efforts to harmonize IGF-I assay results are being undertaken after a recent workshop jointly sponsored by the GH Research Society, the IGF Society, and the IFCC (118), but the effect of residual IGFBP in assayed samples will remain a thorny problem.
The two IGF-I assays used for the GH-2004 project were the DSL-5600 IRMA and the Immunotech A15728 IRMA; their technical aspects have been reported in detail (185) . To minimize IGFBP interference, the DSL assay uses acid-ethanol precipitation, whereas the Immunotech assay uses acidification and excess IGF-II to prevent rebinding of IGF-I. There is good correlation between the two assays, but there is a systematic bias in favor of the DSL assay, which yields values that are about 20% higher than those obtained by the Immunotech assay (185) . The DSL assay is no longer available and has been replaced by the Siemens Immulite assay system, which does not use extraction. No back-to-back comparison between the Immunotech and Immulite assays has been published.
Preanalytical considerations are not of major concern because IGF-I is a stable peptide, and no special precautions are necessary during transport and storage of serum (118, 186) .
Mass-based measurements of IGF-I are being developed and are beginning to approach the necessary sensitivity for measuring IGF-I concentrations in serum (187) (188) (189) (190) and urine (191) . Measurement by MS would alleviate some of the problems with immunoassays, although the issue of removal of (or accounting for) IGFBP would still be a challenge for accurate quantitation.
b. P-III-NP measurement. Serum P-III-NP is currently also measured by immunoassay. Unlike for IGF-I, where a number of commercial and in-house assays are widely employed, there are only two commercial assays in general use: the Orion UniQ RIA and the CIS Biointernational RIA-gnost IRMA. No international reference standard exists for P-III-NP, and there is no information given by the manufacturers regarding the exact nature or source of their standards (natural or recombinant, monomeric or trimeric, human, bovine, or porcine, etc.).
Knowledge about the specificity of either assay with respect to the different immunoreactive forms of circulating P-III-NP is limited. The Orion UniQ assay is described as measuring intact P-III-NP and its higher mol wt forms, but not smaller degradation products found in blood (assay kit instructional pamphlet). The CIS RIA-gnost assay is reported to measure P-III-NP Col 1-3 (intact P-III-NP), but not the Col 1 fragment (assay kit brochure and Ref. 139). These descriptions do not take into account the complexity of immunoreactive P-III-NP species in serum, nor do they identify the epitopes recognized. An early version of the RIA-gnost assay recognized peak IV material (Fig.  8A) , which is thought to at least partially consist of the Col 1 fragment, suggesting that the assay reagents or conditions have changed over time.
The two assays are not directly comparable because they express results in different units (nanograms per milliliter and units per milliliter, respectively), but they show a good correlation (185, 192) , suggesting that they measure a comparable substance(s). Moreover, when the conversion factor of 8 (provided in the RIA-gnost brochure) is used to convert units per milliliter to nanograms per milliliter, values for the normative ranges in the two assays are comparable. It is unclear why the RIA-gnost manufacturer does not use this conversion factor in expression of results. Technical details of the two commercial assays are summarized by Abellan et al. (192) and Cowan and Bartlett (185) . The absence of a universal standard for P-III-NP is a major shortcoming that should be addressed by the antidoping and clinical chemistry communities.
The stability of P-III-NP during storage and transportation has been evaluated and found to be acceptable when serum was stored frozen or kept at 4 C for up to at least 5 d (186, 192) . Two to three freeze-thaw cycles did not significantly affect assay results (192) .
As with IGF-I and all other analytes, a mass-based measurement technique would be highly desirable. Currently there are no reports on attempts to develop MS analysis of P-III-NP in serum. Although its mol wt (ϳ40,000) may act as a deterrent to such efforts, it should be realized that P-III-NP is a homotrimer of a protein that has a mol wt of only about 13,000. The molecular heterogeneity of circulating P-III-NP may be elucidated by MS. However, its low concentration in blood (subnanomolar) still presents a challenge for current MS technology. (156, 157, 193, 194) . Nevertheless, such correction maneuvers are not optimal because they do not represent primary data, and the need for assays that perform in a robust manner over long time periods is evident. History has shown that commercial immunoassays are probably not able to fulfill this requirement. Hence, the need for future assays that do not depend on biologics or commercial suppliers of unique reagents.
d. Implementation. The WADA code requires that a positive test result be confirmed by a second, independent method. Ideally, the two methods should be based on different analytical principles, but currently both IGF-I and P-III-NP measurements are limited to immunoassay measurement. In the case of immunoassays, the WADA code stipulates that the assay used for confirmation needs to recognize a different epitope(s) on the analyte than the original assay. Alternatively, a purification/separation method can be used before immunoassay to eliminate potential crossreactivity. Precise epitope maps are not available for either IGF-I or P-III-NP, but indirect evidence suggests that the diverse antibodies used in the assays recognize different aspects of the analytes. In addition, one of the IGF-I assays used incorporates a purification step. [It should be noted that for the GH isoform test described in Section III.A, the epitopes recognized by the four assays employed are well characterized (90) .] These criteria may be sufficient to satisfy WADA requirements. Nevertheless, for the purpose of independent confirmatory testing, it would be highly desirable to have available mass spectroscopy-based methods that are unquestionably independent and distinct from immunologically based methods.
The biomarker test is poised for general implementation as a WADA-sanctioned test in the near future. It will serve as an important complementary test to the already implemented GH isoform test, providing independent confirmation and a longer window of opportunity. Because of the latter characteristic, it may be suitable for both in-competition and out-of-competition testing. It is important to note that thus far neither the isoform test nor the biomarker test has been scrutinized under legal challenge.
C. Novel approaches
Research is continuing to identify additional indicators for GH use that may be useful for antidoping purposes. In particular, genomic and proteomic approaches are being explored in an attempt to identify a "signature" that would be indicative of exogenous GH use. Mitchell et al. (195) examined transcriptome changes in peripheral blood leukocytes obtained from recreational athletes treated with GH (2 mg/d) for 8 wk. They identified induction or repression of several genes in GH-treated subjects, but the magnitude of transcript changes was small and within the variability range seen among different untreated subjects. None of the genes significantly up-regulated (IGF2, MED18, PDK4) or down-regulated (AREG, ARG1, CYYR1) are classical GH-responsive genes, and disparate responses have been found for some of them (PDK4 and AREG) in different tissues or physiological states. The authors concluded that transcriptome analysis in leukocytes is unlikely to yield a viable antidoping test.
Proteomic approaches to detection of GH use have been employed using serum and peripheral blood leukocytes and either protein chip adsorption or two-dimensional electrophoresis followed by mass spectroscopy (196 -200) . These efforts have identified changes in unexpected proteins, such as free hemoglobin A1 chain, ␤-hemoglobin, transthyretin, apolipoprotein A 1 , and fragments of albumin and Ig in serum, and calgranulins and DAMP (damage-associated molecular pattern) proinflammatory molecules in leukocytes. Some of the serum proteins are acute-phase reactants, and all proteins mentioned show considerable variability. Their physiological significance and potential biological link to GH remains to be established. It is evident from these preliminary data that a considerable amount of work will be required before proteomic approaches will become a realistic tool for antidoping purposes. It is currently not clear whether anonymous/comprehensive or GH-targeted proteomic or genomic inquiries will be more productive in yielding a GH-specific signature. It is also not clear whether the identification of many GH-responsive endpoints is superior to one or a few well-chosen endpoints, or whether it simply increases analytical noise.
Reports on new GH-responsive biochemical markers, such as mannan-binding lectin (201) , will continue to appear in the literature. The specificity and sensitivity of such novel markers will have to be rigorously demonstrated before they are considered as an antidoping strategy. The experience with IGF-I and P-III-NP, two well-established GH biomarkers, suggests that development of a robust biomarker test is a time-consuming process.
IV. Secretagogues
GH secretagogues are peptides or nonpeptidic agents that act to release GH from the pituitary. There is evidence that they are being used by athletes as an indirect method for GH doping. Secretagogues include GHRH and its analogs, ghrelin analogs [known as GH-releasing peptides (GHRP) or GHS (GH secretagogues in a narrower sense), and amino acids (e.g., arginine or ornithine). GHRH acts through the GHRH receptor; GHRP/GHS acts through the ghrelin receptor, also known as the GHS receptor 1a; both receptors are coupled to G proteins and signal primarily though G s ␣ and G q/11 pathways, respectively. Arginine and ornithine have to be given in high doses (e.g., 30 g iv); they are thought to stimulate GH secretion through suppression of somatostatin. General features of secretagogues are that their effect is short-lived and they provide a relatively weak boost in GH exposure compared with what can be achieved by direct GH administration. GH secretagogues are attractive to athletes who want to avoid detection because the GH released is endogenous and therefore not detectable by the GH isoform test.
A. GHRH and its analogs
GHRH is a 44-or 40-amino acid linear peptide secreted by the hypothalamus; it stimulates pituitary somatotroph proliferation and GH production (both synthesis and release). Its fully bioactive shorter version, GHRH(1-29) (sermorelin), was marketed in the 1980s to treat idiopathic GH deficiency in children and also for diagnostic purposes in pituitary disease. It was found to be largely ineffective as a growth promoter, and its use as a thera-peutic agent was abandoned. It is no longer available on the U.S. market. It is unclear whether it exists on the black market for doping purposes. Bioactive GHRH has a very short half-life (ϳ7 min) in blood, being rapidly degraded by dipeptidyl-aminopeptidase IV (202) . Intravenous GHRH administration elicits a spike in plasma GH that peaks (at ϳ10 -25 ng/ml) at 15-30 min and returns to baseline after 120 min. Studies conducted with GHRH in the elderly in an effort to reverse the somatopause have yielded varying degrees of mild elevation of serum IGF-I and changes in body composition, but little improvement in physical performance (203, 204) . Based on its short duration, need for repeated administration, and limited efficacy in GH deficiency or GH insufficiency in the elderly, it is unlikely that GHRH provides significant GH doping "benefits" to the athlete.
There is currently no detection test for GHRH abuse. Its low dosing, short half-life, and structural similarity with endogenous GHRH (which is produced not only in the hypothalamus, but primarily in gut and other extraneural tissues) would present a substantial challenge to development of a detection test.
Newer, long-acting analogs of GHRH, such as tesamorelin and CJC-1295 have been developed; the former is approved by the Food and Drug Administration for treatment of HIV-associated lipodystrophy; the latter has undergone clinical trials. Strategies to increase half-life include amino acid substitutions and other modifications targeting the dipeptidyl-aminopeptidase IV cleavage site at position 2 and incorporating a linker with a reactive group that allows covalent linkage to albumin in vivo after injection. The plasma half-life of tesamorelin is ϳ30 min (205) ; and that of CJC-1295 is 6 -8 d (206) . Despite the relatively short half-life of tesamorelin, once a day administration results in enhanced GH pulsatility over 24 h and a mean IGF-I increase of 108 -122% (205, 207) . Treatment of HIV-associated lipodystrophy with tesamorelin resulted in an 18% loss of visceral fat, suggesting a GHinduced lipolytic effect (207) . Administration of a single dose of CJC-1295 resulted in an elevation of plasma GH trough, but not peak levels, and an ϳ40% increase in IGF-I levels 1 wk later (208) . Thus, it appears that these long-acting GHRH analogs have a moderate enhancing effect on GH secretion and its downstream biomarkers. There is evidence that these drugs have entered the black market (209) .
Currently there is no published method to detect use of these GHRH analogs, but because they differ structurally from native GHRH, unequivocal detection methods should be feasible if sufficient sensitivity can be achieved.
B. Ghrelin mimetics
Ghrelin is an orexigenic peptide produced by the stomach. It is a 28-amino acid, linear peptide that exists both as a 3-octanoylated form and as a nonacylated form. The octanoylated form is bioactive; the biological role of the nonacylated form is currently a matter of debate. In the presence of an intact hypothalamo-pituitary system (i.e., GHRH functionality), ghrelin is a potent secretagogue for GH in vivo. GHRH signaling is crucial for this pronounced ghrelin effect on GH release (210) . Despite its efficacy as a pharmacological agent, the role of ghrelin in the physiological regulation of GH secretion is minor at best. Its main physiological role appears to lie in the area of appetite regulation. Discovery of ghrelin analogs (GHRP, GHS) as well as the ghrelin receptor preceded the identification of ghrelin by many years.
GHRPs are non-native hexapeptides originally derived from enkephalin, including GHRP-6, GHRP-2 (pralmorelin), and hexarelin; other GHS are modified peptides such as tabimorelin, and nonpeptide compounds such as MK-677, L-692,429, SM-130,686, and TZP-101. A considerable number of studies have evaluated the short-term and long-term effects of ghrelin mimetics on the GH-IGF axis. A typical GH response to an iv bolus of ghrelin or GHRP yields a peak serum GH of 70 -110 ng/ml at 15-30 min, with return to baseline at 120 -180 min. Long-term therapy has been attempted for idiopathic GH deficiency or short stature, frailty in the elderly, osteoporosis, and amyotrophic lateral sclerosis. A few representative studies will be cited. For example, a 2-yr study in children with idiopathic GH deficiency or short stature with intranasal GHRP-2 three times a day produced a modest gain in growth velocity but no change in serum IGF-I (211). Oral GHRP-2 in a similar study resulted in an approximate 2-fold increase in GH secretion, a modest increase in growth velocity, and again no change in serum IGF-I (212). Addition of GHRH to the GHRP regimen did not improve outcome (212) . Tabimorelin treatment for 7 d in young, healthy male subjects yielded a 50% increase of serum IGF-I and an attenuation of the GH response over time (213) . A 2-yr, randomized, double-blind trial of daily MK-677 treatment in elderly subjects showed a 1.8-fold increase in GH secretion and a 1.5-fold increase in serum IGF-I, an increase in both lean body mass/water and fat mass, little effect on bone mineral density, a smaller decline in muscle strength than in controls, and no effect on physical function and quality of life (214) . A 1-yr trial of capromorelin in elderly subjects increased IGF-I by 60%, and some performance measures (stair climb and tandem walk) increased, whereas several others did not (215) . The effect was considered insufficient to warrant continuation of the trial or further development of the drug. The topic of ghrelin mimetic and GHRH therapy was reviewed by Hersch and Merriam (216) .
Taken together, these and several other studies indicate that ghrelin mimetics have a moderate effect on GH secretion and IGF-I levels, but they have insufficient impact on growth or physical performance to be considered marketable at this time. The same side effects as those noted with GH treatment were observed, but at a lesser frequency and severity. This observation is congruent with the pharmacological concept that less effect is accompanied by fewer side effects. An undesirable and GH-unrelated side effect of all ghrelin mimetics is increased cortisol production and increased appetite/adipose weight gainboth intrinsic features of the ghrelin system.
Given the relatively mild effect of ghrelin mimetics on overall GH secretion and the uncertainty about the ergogenicity of even large GH doses (see Section VI), it appears unlikely that athletes would derive significant performance-enhancing benefits from abusing ghrelin mimetics or GHRH analogs.
There is evidence that ghrelin mimetics are being offered on the black market for doping purposes (217, 218) . Methods to identify these non-native substances in urine have been developed (219 -222).
C. Amino acids
Large iv doses of certain amino acids (arginine, ornithine, lysine) have GH-releasing activity and are in use diagnostically as a GH stimulation test (especially arginine, 30 g rapidly iv). Even at these large doses they are relatively weak stimuli unless given together with GHRH. These uses of amino acids have been extrapolated to mean that oral arginine supplements are GH stimulators, and the Internet is replete with arginine advertisements. There is no reason to believe that typical oral doses of arginine elicit significant GH release. This can be verified during a protein meal and has indeed been directly shown (223) . Testing for abuse of amino acids is not currently feasible, but may also not be necessary in view of their limited efficacy.
V. IGF-I as a Doping Agent
Since many actions of GH are mediated through IGF-I, it is not surprising that IGF-I is also being abused for the purposes of performance enhancement. IGF-I appears on the WADA list of banned substances. IGF-I is commercially available for medical indications, such as genetic GH resistance and primary IGF-I deficiency. A preparation combining IGF-I with IGFBP3 is not marketed the United States, but clinical trials for certain neurological diseases (amyotrophic lateral sclerosis) are ongoing. The Internet is replete with advertisements for IGF-I and its more potent analogs-des(1-3)IGF-I, R 3 -IGF-I, Long-R 3 -IGF-I, and mechano-growth factor (IGF-IEc or a peptide derived from the E-domain of pro-IGF-I). The former three analogs have low affinity for IGFBPs due to modification of the amino terminus (deletion of residues 1-3, substitution of glutamic acid in position 3 with arginine, and a 13-amino acid amino-terminal extension in addition to the Glu 3 -Arg modification, respectively). The latter is derived from an IGF1 gene splice variant that includes a carboxyterminal sequence encoded by a 3Ј-exon (exon 5) that is excluded from liver IGF-I transcripts. The physiological importance of IGF-IEc is controversial, and the existence of mechano-growth factor as a native peptide is not established (see Ref. 224 for review). IGF-I analogs have been discovered in supplement products sold on the black market (217) . There is also evidence that even IGF-I products strictly intended for in vitro use have entered the supply stream available to athletes (225) .
IGF-I is a mitogenic, anabolic, and metabolically active peptide generated in response to GH in most tissues, with the liver the predominant source. The bioactivity spectra of GH and IGF-I are overlapping but not identical. One prominent example where GH and IGF actions diverge is lipolysis: GH has a direct lipolytic activity, whereas IGF-I does not. The treatment of patients with GH resistance with IGF-I does not completely mimic the treatment of GH deficiency with GH, and the phenotypic features differ (226) . Thus, it cannot be presumed that IGF-I abuse in sports has the identical effect as GH abuse. IGF-I does have anabolic action in numerous tissues, including muscle, and is an important mediator of GH action in muscle. This anabolic action cannot, however, be interpreted as necessarily indicating that IGF-I enhances athletic performance in healthy individuals (see Section VI). In contrast to GH, there is relatively little information on the possible performance-enhancing action of IGF-I in normal human subjects.
Currently, there is no established detection method for IGF-I abuse. Studies evaluating the biomarker approach outlined above for detection of IGF-I abuse are ongoing (227, 228) .
VI. GH as an Ergogenic Substance
GH appears as the ideal ergogenic agent: it is the prototype master anabolic hormone, promoting nitrogen accretion, protein synthesis in numerous tissues including muscle, and physical growth. In addition, it has lipolytic activity, causing adipose tissue to shrink and divert liberated calories toward carbohydrate fuel generation and protein synthesis. GH undeniably exhibits all these activities, which have been documented in numerous in vitro and in vivo studies. Based on these facts, the sports, body-building, and antiaging communities believe that GH must be beneficial for building musculature and therefore physical performance. This apparently reasonable assumption is, however, still a matter of debate as far as athletic performance is concerned, due to the difficulty in demonstrating ergogenicity of GH in scientific studies (229) .
A fundamental principle in endocrinology states that the effect of a hormone is most evident when the hormone is replaced in an individual who is deficient in that hormone. Accordingly, the ergogenic effect of GH should be most obvious in GH-deficient patients when treated with GH. The scientific literature on this point is mixed: some studies show increased stamina, few show increased strength, and some show little effect on parameters related to physical performance. The complexity of GH status (deficiency or excess) on muscle morphology, metabolism, and function has been reviewed in detail by Woodhouse et al. (230) . From that review, it appears that both a deficiency and an excess of GH are deleterious to muscle health. Assessment of physical function in GH deficiency and its response to GH replacement has been the subject of numerous studies, with less than consistent conclusions. The very fact that this is still a subject of investigation after two decades of study attests to the difficulty of settling this issue. A detailed discussion of the many studies addressing the ergogenic effects (or lack thereof) of GH replacement therapy in hypopituitarism is beyond the scope of this review. A recent meta-analysis of 11 randomized, double-blind, placebo-controlled studies concluded that GH replacement improved the exercise performance of GH-deficient patients (231) . Another meta-analysis of muscle strength outcome in eight randomized, double-blind, placebo-controlled studies (some are the same as those included above) concluded that there was no improvement in muscle strength after 6 -8 months of GH replacement (232) . The authors point out that longer duration (years) of therapy might have resulted in increased strength. A recent study of cardiovascular function in patients given physiological replacement doses of GH (mean, 0.64 mg/d) found no improvement in exercise performance, in contrast to earlier studies using higher GH doses (233) . Taken together, the studies in GH deficiency suggest that there probably is an overall improvement in physical function with GH replacement, but this is variable, complex in nature, less than compelling, and not universally accepted. Thus, even in the "ideal" setting of GH deficiency, it is difficult to unequivocally demonstrate an ergogenic effect of GH.
The question then arises whether ergogenicity can be shown in normal (i.e., GH-replete) subjects, which includes both untrained individuals and athletes. Based on the above-mentioned endocrine/biological concept, it would be predicted that this may be more difficult. A number of studies examining the effect of GH on athletic performance have been conducted. A systematic literature review by Liu et al. (234) summarized the results of 27 randomized, controlled trials involving 303 young, lean, physically fit subjects receiving GH at an average dose of ϳ2.5 mg/d-a 5-to 10-fold excess over the physiological GH production rate. While there were the expected changes in body composition (increased lean body mass and marginally lower fat mass), there were no differences in strength or exercise capacity between those taking GH and those who did not. The authors point out the limitations of the studies in terms of duration and dose of GH, which may be less than what is typically used by athletes. Nevertheless, the typical side effects associated with GH administration (edema, arthralgias, carpal tunnel syndrome, sweating) were observed in 15-44% of the participants. A list of typical adverse effects seen with GH administration is given in Table 4 .
There are relatively few controlled studies of GH effects in trained athletes. The Mitchell report (Ref. 4 , pages 9 -10) relates the impression of athletes that GH did not have a positive effect on their performance. Deyssig et al. (235) showed in a double-blind, placebo-controlled trial that GH [30 g/kg ⅐ d (or ϳ2-2.5 mg/d) for 6 wk] had no effect on muscle strength. Lange et al. (236) showed that acute GH administration (2.5 mg 4 h before exercise) did not increase bicycling performance measured as speed or VO 2 but had a deleterious effect in two cyclists. Meinhardt et al. (237) , in a double-blind, placebo-controlled study of recreational athletes, showed that GH (2 mg/d for 8 wk) had no effect on muscle strength (dead lift), power (jump height), or endurance (VO 2 max) but did improve sprint capacity by 5.5% in men but not women (by 2.5%; not significant). Testosterone coadministration in men enhanced the effect of GH. Adverse effects typical for GH administration were seen in a significant number of the treated subjects. This isolated improvement in anaerobic muscle performance during sprinting is somewhat unexpected, especially because other anaerobic muscle functions were not affected. The authors state that athletic significance of this finding is uncertain, but they also speculate that the improvement might translate into a 0.4-sec advantage in a 100-m sprint.
In view of the overall scientific literature, the evidence for GH as an ergogenic substance in healthy humans is weak. Yet athletes continue GH abuse in the belief that it improves their performance. Numerous reasons can be given why the scientific literature does not reflect GH use in the sports arena: GH doses are too low; duration of treatment is not long enough; GH in conjunction with anabolic steroids, insulin, and other doping agents may have greater ergogenicity than when given alone; GH in combination with exercise is particularly potent; athletes react to GH in a different manner than nonathletes, etc. While all of these arguments have some validity and should not be readily dismissed, perhaps the most pertinent are those regarding dose and duration. Dosages and injection patterns among athletes are difficult to assess because of the lack of documentation and prevailing secrecy. Ehrnborg et al. (2) mention doses of 3-8 mg three to four times a week but state that the mean daily dose is mostly ϳ1.3 mg. Saugy et al. (238) estimate that, based on underground information, athletes inject 3-8 mg three to four times a week. The reliability of such underground information is uncertain because athletes themselves (or their trainers) may not know in detail what or how much is being administered. Nature has provided for an excellent model of the effects of high-dose, long-duration GH exposure: the patient with acromegaly. Acromegaly is caused by excess production of GH, usually by a benign pituitary tumor. It is a disease with insidious onset; the delay between onset and diagnosis is estimated as at least 7-10 yr (239) . Acromegaly has a high morbidity and carries a 1.5-to 3-fold increase in mortality, with a direct relationship between GH levels and risk of premature death (240) ; it adversely affects many tissues and functions critical to physical performance (joints, heart and skeletal muscle, connective tissue, nerve entrapment, hypertension, metabolic derangements, diabetes mellitus, etc.) (241) . Physical performance is clearly impaired in established acromegaly due to numerous physical and metabolic reasons. Therefore, high doses of GH over a long time are not performance enhancing. It could be argued that there may be an early phase of acromegaly, before the establishment of physical and metabolic derangements, when the high prevailing GH levels are ergogenic. This would be akin to the athlete abusing GH. However, with the exception of one spectacular case self-report (242) , there is no evidence that patients with acromegaly experience such a phase of enhanced physical functioning. Rather, the disease progresses in silence for years before disfigurement leads to the diagnosis. Of interest, the patient in the cited case report was still growing at age 22, with a height increase of 6 inches (15.2 cm) over the preceding 4 yr. Given his pituitary tumor, this phenomenon is best explained by hypogonadism, calling into question the contribution of high endogenous testosterone levels to the postulated ergogenic effect high GH levels. Despite this report, the general lesson taught by acromegaly does not support the notion that high-dose GH is more ergogenic than low-dose GH.
Another reason sometimes given for the use of GH by athletes is the belief that GH accelerates recovery from injury. There is only limited information about this issue in the scientific literature. Involvement of GH in healing may be postulated based on the fact that collagen turnover increases after GH administration (see Section III.B.1). However, it is unknown whether after an injury GH plays a role in this response or whether local factors operating at the injury site are responsible. Furthermore, it is unknown whether supraphysiological GH concentrations confer any advantage over the normal physiological response of the GH-IGF system. One recent study examined collagen synthesis in patellar tendon and quadriceps muscle in response to 14 d of high-dose GH treatment (33-50 g/kg ⅐ d, ϳ2-4 mg/d) in noninjured young male volunteers; GH treatment increased collagen protein synthesis 1.3-fold over placebo (significant) in tendon and 5.8-fold (not significant) in muscle (243) . Another study examined the effect of three doses of GH (15, 30 , and 60 g/kg ⅐ d, ϳ1, 2, and 4 mg/d) on tibial fracture healing (244) . At the highest dose, GH accelerated fracture healing by 29% in patients with closed fractures, but had no significant effect on the healing of open fractures. The two lower doses of GH had no discernible effect on fracture healing (244) . These findings need to be corroborated and expanded before firm conclusions can be drawn about the effect of GH on recovery from injury. Furthermore, the response of different types of injury and tissues to GH treatment, as well as the doses required need to be investigated before the significance of GH for recovery from athletic injuries becomes clear. It is of interest that promising early trials of GH therapy for burns (245, 246) have not been widely accepted as a therapeutic modality. The currently available evidence is insufficient to warrant the use of GH to promote healing of sports injuries.
A third reason for GH misuse is the belief by athletes that the lipolytic activity of GH results in weight loss, which they believe to be beneficial to athletic performance. However, GH administration does not typically result in a net weight change because the loss of fat is compensated for by a gain in lean body mass [of which a substantial part (50 -80%) represents retained fluid]. This is true in the GH-deficient patient on GH replacement therapy as well as in normal subjects, including athletes, taking GH (237, 247) .
The conviction in athletic circles that GH is a performance-enhancing substance appears to run deep, despite assertions to the contrary cited in the Mitchell report (4). An athlete's personal sense of what makes him or her perform better should not be easily dismissed. Neither should the powers of a placebo effect, hearsay, peer/coach pressure, and advertising be underestimated. It should also be remembered in this context that an ergogenic effect of androgens was questioned by the scientific community for years before their performance-enhancing potency was proven. In the final analysis, even with the best scientific evidence it will be impossible to prove a negative, namely that GH does not have an ergogenic effect. Nevertheless, given what is known, the burden of proof lies with those who advocate GH use in the belief that it enhances physical performance in healthy humans. Education of athletes, trainers and other sports personnel about the facts known regarding GH effects on performance should be undertaken by sports organizations as part of their antidoping strategy. This education should also include information about the short-term and long-term side effects of high-dose GH use. Given the dearth of scientific evidence for ergogenicity and the potential serious adverse effects on health, it seems ill-advised to use GH for uncertain performance enhancement in healthy individuals.
VII. Summary and Conclusions
GH is reported to be widely abused by athletes in many types of sport. The attractiveness of GH lies in its anabolic and lipolytic activities, combined with an aura of "undetectability." GH abuse extends beyond professional sports and is also present among adolescents engaged in sports in schools. This widespread use presents a public health problem because GH use is accompanied by adverse effects, and long-term use can lead to serious morbidity.
Because GH is secreted in a pulsatile manner and therefore fluctuates widely in blood, a high serum GH cannot be interpreted as evidence for exogenous GH administration.
GH used for doping purposes is said to be like a natural substance and therefore not detectable. However, pituitary GH consists of a number of molecular variants (isoforms), whereas recombinant GH corresponds to only one (the most prevalent) isoform, 22K-GH. This difference forms the basis of a detection test, where the ratio between 22K-GH and pituitary GH (a mixture of isoforms) is used as the endpoint. The isoform detection test performs well, but has a limited window of opportunity (12-24 h after the last GH injection). It has been a WADA-sanctioned and generally implemented test for over 2 yr; positive results have been few, presumably because of the short window of detection opportunity. The isoform test can be circumvented by using cadaveric GH (with attendant risk of acquiring Creutzfeld-Jakob disease) or using GH secretagogues (resulting in only mild GH stimulation).
A second detection test for GH abuse, the biomarker test, is based on measurement of biochemical effects of GH administration. Serum levels of IGF-I and P-III-NP rise after GH administration and remain elevated for several days to weeks after a GH dose. They are not completely specific for GH, but extensive validation studies have resulted in a discriminant formula that allows distinction of GH-induced elevation from most if not all nonspecific stimuli. The biomarker test has a window of opportunity of several days-realistically probably 5-7 d. It is scheduled to be implemented by WADA in time for the London 2012 Olympiad.
The immunoassays currently used for IGF-I and P-III-NP are somewhat problematic because of the lack of consistency over time and notorious interference by IGFBPs (IGF-I), and insufficient standardization due to absence of an international reference standard (P-III-NP). The development of mass-based identification and quantification methods that do not depend on antibodies or poorly defined/impure reference standards is highly recommended as MS-based technology becomes feasible.
Detection of doping substances (such as anabolic steroids) in urine has been a time-honored and successful tradition in sports. This methodology is not easily applicable to polypeptides such as GH, IGF-I, or P-III-NP. The reasons are multiple and include extremely low levels of residual peptide in urine, renal factors impinging on excretion, lack of evidence that urinary peptide concentra-tion reflects plasma concentration or overall production/ dose, and insufficient scientific background information on how peptide excretion is regulated. The fact that for the polypeptides under consideration here, quantitative differences rather than qualitative differences (such as e.g., a foreign substance or an abnormal glycosylation pattern) are determined presents an additional challenge to urine testing. For all these reasons, it is probably unwise to pursue the elusive goal of a urine test for detection of GH abuse. It is likely more productive to expend efforts to convince athletes that blood testing is necessary for these substances and to develop ultrasensitive methods that permit minimization of the required blood volume. The former should not be as difficult as is assumed because blood testing is already well-accepted in the blood doping field.
Saliva is under consideration as an ideal biological fluid that would allow noninvasive testing for doping substances. However, obstacles similar to those mentioned for urine would have to be overcome. The limited data available about salivary GH and IGF-I do not appear encouraging.
GH secretagogues of the GHRH and particularly GHRP/GHS variety are likely being used as doping agents in an effort to boost endogenous GH production, while at the same time evading detection by the GH isoform test. The boost in GH levels is far smaller than what can be achieved with direct GH administration, and the ergogenic effect (if any) would be significantly less. Amino acids (arginine, ornithine, lysine) are ineffective in boosting GH secretion unless they are given as large iv bolus doses. Urine tests are being developed for GHRP/GHS and possibly GHRH analogs; this is feasible because these compounds are structurally different from their endogenous counterparts.
Doping with IGF-I is the newest form of "GH doping;" there is forensic evidence that IGF-I and its congeners are being used. To date, no test to detect IGF-I abuse is available, but the above-mentioned GH biomarker test (see Section III.B.1) and variations thereof are being studied as a detection strategy. Obviously, the GH isoform test would not be applicable, nor would urinary IGF-I testing be suitable for the reasons outlined above.
The question regarding the ergogenicity of GH has been asked for many years. The notion that GH is a performance-enhancing substance is based on its known anabolic action, amplified by its lipolytic action. Countless studies have documented the effect of GH on muscle mass, muscle architecture, metabolism, and function in vitro, and there is no doubt about the anabolic effects of GH, especially in the context of GH deficiency. The picture is less clear in GH sufficiency. Furthermore, the link between muscle mass, muscle function, and physical performance in vivo is less than straightforward. Accumulating scientific evidence in normal humans (including athletes) has for the most part failed to demonstrate a significant ergogenic effect of GH in supraphysiological doses, although perhaps in lower doses than those speculated to be used by athletes. The best model of high-dose, long-term GH "administration," acromegaly, also fails to support an ergogenic effect. There is anecdotal evidence [from the Mitchell report (4) ] that athletes recognize that GH does not enhance their performance. Given this overall evidence, the burden of proof that GH is ergogenic lies with those advocating its use. Sports organizations should educate athletes and trainers about these facts in an effort to combat GH doping, an expensive, probably poorly effective, medically hazardous form of unfair behavior. 
